Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) EPS (Weighted Average and Diluted) (2021 - 2025)

IDEAYA Biosciences' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.94 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 39.35% year-over-year to -$0.94; the TTM value through Dec 2025 reached -$1.28, up 61.9%, while the annual FY2025 figure was -$1.28, 61.9% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.94 at IDEAYA Biosciences, down from $1.36 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.36 in Q3 2025 and bottomed at -$1.55 in Q4 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.52 (2021), against an average of -$0.48.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 1020.0% in 2023 before it skyrocketed 326.67% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.52 in 2021, then fell by 3.63% to -$0.54 in 2022, then rose by 3.7% to -$0.52 in 2023, then crashed by 198.08% to -$1.55 in 2024, then skyrocketed by 39.35% to -$0.94 in 2025.
  • Per Business Quant, the three most recent readings for IDYA's EPS (Weighted Average and Diluted) are -$0.94 (Q4 2025), $1.36 (Q3 2025), and -$0.88 (Q2 2025).